



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604773, ✉gmc-rc@esic.nic.in

File No.: U-25/12/NSQ/2021-MedV (E-1119) / 65 Dated:- 27-02-2026

To,

Director (Medical) Delhi / Director (Medical) Noida,
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents – All ESIC Hospitals,
Directors, ESI Scheme, All States

NSQ-04/2026

Subject: **Declaration of Drug “Not of Standard Quality” on Testing – reg**

Sir/Madam

It is hereby informed that the Drug/item has been reported as “Not of Standard Quality”. The details of the drug reported NSQ is given below:

Sample taken in Premises	Name of the Firm (M/s)	Item Name/ (Brand Name)	RC No/ Item No/ Page No	Batch No./ DOM/ D/OE	Name of the Laboratory/ Report No. & Date	Reason of NSQ
ESI Hospital Rajamahendravaram -533 103 East Godavari District	Morepen Laboratories Limited	Tab. Ondansetron 8 mg Ondoc 8	149 2250	F510767 A 09-2025 08-2027	Government Analyst, Drugs Control Laboratory, Vijayawada 152/KYG/APS DTL/2025 Dated: 12/01/2026	The Sample Fails in Dissolution Test at S1 and S2 level for Ondansetron as per I.P. (copy enclosed).

In context to above, it is directed to:

1. Medical Store to immediately withdrawn stock from respective sub-stores/Dispensaries/patient care area.
2. Medical Store to immediately write a letter to vendor for replacement of stock with another batch, within 15 days or to pick up stock and return the payment made other process of risk purchase to be initiated and recover cost of testing (if any) from the vendor.
3. Stop use of the batch of the above-mentioned item immediately which has been reported as “Not of Standard Quality”.
4. Initiate action as per relevant clause of Terms & Conditions of respective DG-ESIC Tender Enquiry/RC.
5. Stop accepting said NSQ drug of this batch in future orders.

6. Maintained record of action taken at in respective user units.

This issues with the approval of Medical Commissioner (Procurement).

Enclosures: As above

Yours Sincerely,
Digitally signed by
Sanjiv Kochhar
Date: 27-02-2026
Dy. Medical Commissioner
15:22:54
(Rate Contract)

Copy to:

1. The Drug Controller General of India, CDSCO, CIG Road, New Delhi- 110002 (Email: dci@nic.in).
2. Office of Deputy Drug Controller (I), Central Drugs Standard Control Organisation Baddi, (Container Corporation of India Ltd. Complex) Village- Sheetalpur, Tehsil-Baddi, District- Solan, Himachal Pradesh-173205 (Email: chandigarh@cdsco.nic.in)
3. Morepen Laboratories Limited, 2nd Floor, Tower - C, DLF Cyber Park, Udyog Vihar - III, Sector - 20, Gurugram - 122016 (Haryana) (Email: yadvinder.singh@morepen.com, institution@ morepen.com,)
4. Morepen Laboratories Limited, Unit-V, Plot No.12-c, Sector-2, Parwanoo, Dist. Solan (H.P.) -173 2206.
5. Website Content Manager with request for uploading on ESIC website.
6. Guard file